Impact of MHC Antigen Expression on Breast Cancer Survival
Author Information
Author(s): H.-O. Wintzer, M. Benzing, S. von Kleist
Primary Institution: Institute of Immunobiology, Medical Faculty, University of Freiburg
Hypothesis
Does the expression of MHC antigens influence the survival of breast cancer patients?
Conclusion
The study found no significant influence of MHC antigen expression on the prognosis of breast cancer patients.
Supporting Evidence
- The expression of P2m, HLA-A,B,C, and HLA-DR was significantly lower in malignant tumors compared to benign lesions.
- All benign tumors were positive for P2m and HLA-A,B,C, while only 10 out of 77 carcinomas were positive for HLA-DR.
- Follow-up data revealed no influence of MHC antigen expression on overall or disease-free survival.
Takeaway
The study looked at how certain proteins in breast cancer cells affect patient survival, but found that they don't really make a difference.
Methodology
The study analyzed 77 malignant and 31 benign breast lesions for MHC antigen expression and related findings to patient survival data.
Limitations
The follow-up period was relatively short, and the study suggests that larger sample sizes and longer follow-up are needed for definitive conclusions.
Participant Demographics
Patients ranged in age from 28 to 83 years, with a mean age of 60.9 years for cancer patients and 44.6 years for benign lesion patients.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website